Ask about this productRelated genes to: IL7R antibody
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: IL7R antibody
Related articles to: IL7R antibody
- Relapsed acute lymphoblastic leukemia (ALL), particularly with central nervous system (CNS) involvement, remains a major cause of treatment failure and is inadequately controlled by existing antibody-drug conjugates (ADCs) with tubulin inhibitors. To address this limitation, we developed IL-7Rα-targeted monoclonal antibodies and identified clone 577 as the lead candidate. Using this antibody, we generated ADCs conjugated with either monomethyl auristatin E (MMAE) or the highly potent DNA-damaging payload-PNU-159682 (PNU). In head-to-head comparisons, 577-PNU showed >50-fold greater potency than 577-MMAE in vitro and induced complete tumor regression in xenografts at a 20-fold lower dose. Additionally, 577-PNU provided durable systemic disease control and markedly reduced leukemic infiltration in the brain and spinal cord in both preventive and established murine CNS disease models, offering direct evidence of effective CNS penetration. Safety assessments demonstrated stable body weight, normal hematology and serum biochemistry, and no treatment-related pathologies. Collectively, these findings provide the first preclinical evidence that IL-7Rα-directed ADCs armed with DNA-targeting payload PNU-159682 can achieve durable elimination of systemic and CNS leukemia at tolerable doses, demonstrating both clinical feasibility and CNS disease control, and establishing a compelling rationale for their translational and clinical development in relapsed and refractory ALL. - Source: PubMed
Publication date: 2026/04/27
Yang ShiqiAnzai TakahiroTsumura RyoFuchigami HirobumiHamada MotochikaYuda JunichiroIkuta KoichiYasunaga Masahiro - While adjuvant immunotherapy and BRAF/MEK inhibitors improve the outcomes for BRAF V600-mutant stage III melanoma, comparisons of long-term survival and safety of these therapeutic modalities are currently lacking in Chinese patients. We retrospectively analyzed data from patients with resected stage III BRAF V600-mutant melanoma who received adjuvant therapy between June 2013 and December 2023 across three centers in China. Note that 122 patients were included and categorized into interferon ( = 25), aPD-1 ( = 18), D/T ( = 62), and BRAFi/aPD-1 ( = 17) cohorts. The D/T group demonstrated a significantly longer median RFS compared to the interferon and aPD-1group (22.7 vs. 11.9 months, = 0.005; vs. 12.5 months, < 0.001). Similar results were obtained by restricted-mean-survival-time model. Patients who continued D/T beyond 1 year exhibited significantly improved RFS and DMFS compared to those who discontinued at 1 year duration (NR vs. 22.0 months, = 0.048; NR vs. 22.5 months, = 0.026). NOTCH4 and IL7R mutations may serve as prognostic and predictive biomarkers for long-term survival and targeted-immunotherapy efficacy, respectively. Adjuvant therapy with D/T may represent the most effective treatment strategy for Chinese patients with stage III melanoma harboring BRAF V600 mutations. A combination of BRAF-targeted therapy and aPD-1 immunotherapy provided comparable efficacy and may be an alternative for a specific patient. - Source: PubMed
Publication date: 2026/04/25
Zhang RongchengLiang YaoLi JingjingChen QianqiDing YaWen XizhiZhao BaiweiZheng WeiWu JunwanZhang QiongChen ZiluanDing QiuyueChen LinbinLi RenaiLi KeZhou QimingZhang XiaoshiLi Dandan - Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease that has increasingly been associated with dysregulated mitochondrial quality control and dynamics. However, the molecular mechanisms underlying these alterations remain incompletely understood. This study aimed to systematically identify and validate candidate biomarkers related to mitochondrial dynamics in IPF and to characterize their cell-type specificity and putative regulatory relationships. - Source: PubMed
Publication date: 2026/04/23
Wang YongbinCheng PengMeng ZixiangZhang YingLi YanFeng Feifei - Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single day production of non-activated CAR T-cells engineered to secrete interleukin-18 (IL-18), a pro-inflammatory cytokine that enhances T-cell function. These non-activated CART-IL18 cells exhibit robust anti-tumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of naïve-like non-activated CAR T-cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of α-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18-enhanced, activation-free CAR T product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T. - Source: PubMed
Publication date: 2026/04/16
Durgin Joseph SSeo Shin HKazmi ShadabValentić BakirLeff ChloeMarkovska MartinaJin XiaolingShen FengBerjis AbdullaMukherjee NandanaSannecy AshwinPlesa GabrielaGabunia KhatunaScholler JohnGill Saar IO'Connor Roddy SJune Carl HGhassemi Saba - Natural killer (NK) cells are promising candidates for cancer immunotherapy due to their safety and potent anti-tumor activity. However, their therapeutic efficacy is often limited by poor persistence and activity within the tumor microenvironment (TME) caused by a lack of essential cytokines. - Source: PubMed
Publication date: 2026/03/30
Wang ChunliKim SeokminKong Ling-ZuJang InhwanJo SeonaLee SunyoungLee Soo YunKim Kee KKim Tae-Don